COGNITE
6.4.2020 18:02:08 CEST | Business Wire | Press release
Cognite , a global industrial DataOps and AI software-as-a-service (SaaS) company, was announced as the 2019 Google Cloud Technology Partner of the Year for Manufacturing. Cognite currently supports the full-scale digital transformation of heavy-asset industries around the world, empowering industrial companies to save on costs, reduce environmental footprints to improve sustainability and increase profits made possible through Cognite Data Fusion (CDF).
This international award recognizes one Partner that has implemented multiple Google Cloud technologies to demonstrate how they work together easily to deliver solutions based on individual customer needs.
“We appreciate being recognized for creating value through our software products by turning historical and real-time industrial data into insights. We have seen a number of our manufacturing clients develop and deliver new digital services and even transform their business model as a result of using Cognite Data Fusion,” said Dr. John Markus Lervik, Co-Founder and CEO of Cognite. “It is important for us to make a true impact on our customers while shaping the digital future of the world’s largest, most vital industries.”
“With Cognite making live and contextualized data available, we at Framo, an Alfa Laval company, are able to create our own software applications to predict the status of our equipment, allowing us to plan efficient maintenance. The new system sends intelligent data on our pumps, so we can predict how the pumps will perform in the future. This has enabled us to sign a groundbreaking long term smart contract with our customer Aker BP,” explains Trond Petter Abrahamsen, Managing Director of Framo Services AS.
“We’re proud to recognize Cognite as our Technology Partner of the Year for Manufacturing,” said Kevin Ichhpurani, Corporate Vice President, Global Ecosystem at Google Cloud. “Cognite’s data capabilities, running on Google Cloud, can help manufacturers leverage data to optimize processes and operate more efficiently. We look forward to a continued partnership with Cognite to help manufacturing businesses digitally transform with Google Cloud.”
Cognite Data Fusion is an industrially specialized DataOps and AI platform to optimize manufacturing facilities intelligently by reducing downtime, improving equipment effectiveness, and optimizing forecasting. Through integrated hybrid AI analytics tools, advanced visualization in real-time dashboards, and low-code application development services, Cognite Data Fusion enables heavy asset customers to operationalize and scale their digital programs to unlock ROI at scale.
Cognite has consistently produced proven results for the heavy asset industry, which accounts for around 20-30% of the gross domestic product worldwide, with main verticals in energy and oil & gas, power & utilities, and manufacturing. Operating costs have been reduced by 15-18% through digitalization of the industrial assets and work processes. Cognite Data Fusion utilizes Google Cloud services like Cloud Bigtable, Kubernetes Engine, Stackdriver, Pub/Sub, Cloud spanner, Cloud Storage, Cloud SQL, Auto ML, and ML Engine.
About Cognite
Cognite is a global industrial AI Software-as-a-Service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world. Their key product, Cognite Data Fusion (CDF), empowers companies with contextualized OT/IT data to drive industrial applications that increase safety, sustainability, and efficiency, and drive revenue. www.cognite.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200406005628/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom